Coxsackievirus B3 engineered to contain microRNA targets for muscle-specific microRNAs displays attenuated cardiotropic virulence in mice

Journal of Virology

Volumn 89, Issue 2, 2015, Pages 908-916

  He, Feng ^a   Yao, Hailan ^a   Wang, Jianmin ^b   Xiao, Zonghui ^a   Xin, Le ^a   Liu, Zhuo ^a   Ma, Xiaolin ^a   Sun, Juan ^a   Jin, Qi ^b   Liu, Zhewei ^a  

^a CAPITAL INSTITUTE OF PEDIATRICS   (China)

^b INSTITUTE OF PATHOGEN BIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGONAUTE 2 PROTEIN; COXSACKIE VIRUS B3 VACCINE; MICRORNA; MICRORNA 133; MICRORNA 206; UNCLASSIFIED DRUG; VIRUS VACCINE;

5' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; COXSACKIE VIRUS B3; COXSACKIE VIRUS INFECTION; DRUG EFFICACY; DRUG RESPONSE; GENE EXPRESSION; GENE TARGETING; HEART MUSCLE CELL; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; SKELETAL MUSCLE; SURVIVAL RATE; VIRAL TROPISM; VIRUS GENOME; VIRUS TITRATION; VIRUS VIRULENCE; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; ENTEROVIRUS B; GENETICS; HEART; HUMAN; MALE; MUSCLE; PHYSIOLOGY; VIROLOGY; VIRULENCE; VIRUS REPLICATION;

COXSACKIEVIRUS; MURINAE; MUS;

ANIMALS; CELL LINE; ENTEROVIRUS B, HUMAN; HEART; HUMANS; MALE; MICE, INBRED BALB C; MICRORNAS; MUSCLES; VIRAL TROPISM; VIRULENCE; VIRUS REPLICATION;

EID: 84920836379     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02933-14     Document Type: Article

References (35)

1. Fairweather D, Rose NR. 2007. Coxsackievirus-induced myocarditis in mice: a model of autoimmune disease for studying immunotoxicity. Methods 41:118-122. http://dx.doi.org/10.1016/j.ymeth.2006.07.009.
2. Gauntt CJ, Tracy SM, Chapman N, Wood HJ, Kolbeck PC, Karaganis AG, Winfrey CL, Cunningham MW. 1995. Coxsackievirus-induced chronic myocarditis in murine models. Eur Heart J 16(Suppl O):56-58. http://dx.doi.org/10.1093/eurheartj/16.suppl_O.56.
3. Esfandiarei M, McManus BM. 2008. Molecular biology and pathogenesis of viral myocarditis. Annu Rev Pathol 3:127-155. http://dx.doi.org/10.1146/annurev.pathmechdis.3.121806.151534.
4. Tam PE. 2006. Coxsackievirus myocarditis: interplay between virus and host in the pathogenesis of heart disease. Viral Immunol 19:133-146. http://dx.doi.org/10.1089/vim.2006.19.133.
5. Brown BD, Venneri MA, Zingale A, Sergi SL, Naldini L. 2006. Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med 12:585-591. http://dx.doi.org/10.1038/nm1398.
6. Kelly EJ, Nace R, Barber GN, Russell SJ. 2010. Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. J Virol 84: 1550-1562. http://dx.doi.org/10.1128/JVI.01788-09.
7. Barnes D, Kunitomi M, Vignuzzi M, Saksela K, Andino R. 2008. Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines. Cell Host Microbe 4:239-248. http://dx.doi.org/10.1016/j.chom.2008.08.003.
8. Centers for Disease Control and Prevention. 1999. Impact of vaccines universally recommended for children-United States, 1900-1998. JAMA 281:1482-1483. http://dx.doi.org/10.1001/jama.281.16.1482.
9. Cova L. 2014. Advances and challenges in the development of therapeutic DNA vaccines against hepatitis B virus infection. Curr Gene Ther 14:149-160. http://dx.doi.org/10.2174/1566523214666140509102644.
10. Jang YH, Byun YH, Lee YJ, Lee YH, Lee KH, Seong BL. 2012. Coldadapted pandemic 2009 H1N1 influenza virus live vaccine elicits crossreactive immune responses against seasonal and H5 influenza A viruses. J Virol 86:5953-5958. http://dx.doi.org/10.1128/JVI.07149-11.
11. Kelly EJ, Hadac EM, Greiner S, Russell SJ. 2008. Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med 14:1278-1283. http://dx.doi.org/10.1038/nm.1776.
12. Townley-Tilson WH, Callis TE, Wang D. 2010. MicroRNAs 1, 133, and 206: critical factors of skeletal and cardiac muscle development, function, and disease. Int J Biochem Cell Biol 42:1252-1255. http://dx.doi.org/10.1016/j.biocel.2009.03.002.
13. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, Segnalini P, Gu Y, Dalton ND, et al. 2007. MicroRNA-133 controls cardiac hypertrophy. Nat Med 13:613-618. http://dx.doi.org/10.1038/nm1582.
14. Liu Z, Carthy CM, Cheung P, Bohunek L, Wilson JE, McManus BM, Yang D. 1999. Structural and functional analysis of the 5' untranslated region of coxsackievirus B3 RNA: in vivo translational and infectivity studies of full-length mutants. Virology 265:206-217. http://dx.doi.org/10.1006/viro.1999.0048.
15. Yao H, Zhang Y, He F, Wang C, Xiao Z, Zou J, Wang F, Liu Z. 2012. Short hairpin RNA targeting 2B gene of coxsackievirus B3 exhibits potential antiviral effects both in vitro and in vivo. BMC Infect Dis 12:177. http://dx.doi.org/10.1186/1471-2334-12-177.
16. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am J Hyg 27:493-497.
17. He F, Yao H, Xiao Z, Han J, Zou J, Liu Z. 2014. Inhibition of IL-2 inducible T-cell kinase alleviates T-cell activation and murine myocardial inflammation associated with CVB3 infection. Mol Immunol 59:30-38. http://dx.doi.org/10.1016/j.molimm.2013.12.004.
18. Zhang Q, Xiao Z, He F, Zou J, Wu S, Liu Z. 2013. MicroRNAs regulate the pathogenesis of CVB3-induced viral myocarditis. Intervirology 56: 104-113. http://dx.doi.org/10.1159/000343750.
19. Elia L, Quintavalle M, Zhang J, Contu R, Cossu L, Latronico MV, Peterson KL, Indolfi C, Catalucci D, Chen J, Courtneidge SA, Condorelli G. 2009. The knockout of miR-143 and-145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ 16:1590-1598. http://dx.doi.org/10.1038/cdd.2009.153.
20. Liu N, Bezprozvannaya S, Williams AH, Qi X, Richardson JA, Bassel-Duby R, Olson EN. 2008. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 22:3242-3254. http://dx.doi.org/10.1101/gad.1738708.
21. Diederichs S, Haber DA. 2007. Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression. Cell 131:1097-1108. http://dx.doi.org/10.1016/j.cell.2007.10.032.
22. Brown BD, Gentner B, Cantore A, Colleoni S, Amendola M, Zingale A, Baccarini A, Lazzari G, Galli C, Naldini L. 2007. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol 25:1457-1467. http://dx.doi.org/10.1038/nbt1372.
23. Heiss BL, Maximova OA, Thach DC, Speicher JM, Pletnev AG. 2012. MicroRNA targeting of neurotropic flavivirus: effective control of virus escape and reversion to neurovirulent phenotype. J Virol 86:5647-5659. http://dx.doi.org/10.1128/JVI.07125-11.
24. Sisk JM, Witwer KW, Tarwater PM, Clements JE. 2013. SIV replication is directly downregulated by four antiviral miRNAs. Retrovirology 10:95. http://dx.doi.org/10.1186/1742-4690-10-95.
25. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. 2005. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 309:1577-1581. http://dx.doi.org/10.1126/science.1113329.
26. Norman KL, Sarnow P. 2010. Modulation of hepatitis C virus RNA abundance and the isoprenoid biosynthesis pathway by microRNA miR-122 involves distinct mechanisms. J Virol 84:666-670. http://dx.doi.org/10.1128/JVI.01156-09.
27. Roberts AP, Lewis AP, Jopling CL. 2011. miR-122 activates hepatitis C virus translation by a specialized mechanism requiring particular RNA components. Nucleic Acids Res 39:7716-7729. http://dx.doi.org/10.1093/nar/gkr426.
28. Tong L, Lin L, Wu S, Guo Z, Wang T, Qin Y, Wang R, Zhong X, Wu X, Wang Y, et al. 2013. MiR-10a* upregulates coxsackievirus B3 biosynthesis by targeting the 3D-coding sequence. Nucleic Acids Res 41:3760-3771. http://dx.doi.org/10.1093/nar/gkt058.
29. Wang L, Qin Y, Tong L, Wu S, Wang Q, Jiao Q, Guo Z, Lin L, Wang R, Zhao W, et al. 2012. MiR-342-5p suppresses coxsackievirus B3 biosynthesis by targeting the 2C-coding region. Antivir Res 93:270-279. http://dx.doi.org/10.1016/j.antiviral.2011.12.004.
30. Ye X, Liu Z, Hemida MG, Yang D. 2011. Targeted delivery of mutant tolerant anti-coxsackievirus artificial microRNAs using folate conjugated bacteriophage phi29 pRNA. PLoS One 6:e21215. http://dx.doi.org/10.1371/journal.pone.0021215.
31. Yen LC, Lin YL, Sung HH, Liao JT, Tsao CH, Su CM, Lin CK, Liao CL. 2013. Neurovirulent flavivirus can be attenuated in mice by incorporation of neuron-specific microRNA recognition elements into viral genome. Vaccine 31:5915-5922. http://dx.doi.org/10.1016/j.vaccine.2011.09.102.
32. Jin H, Lv S, Yang J, Wang X, Hu H, Su C, Zhou C, Li J, Huang Y, Li L, et al. 2011. Use of microRNA Let-7 to control the replication specificity of oncolytic adenovirus in hepatocellular carcinoma cells. PLoS One 6:e21307. http://dx.doi.org/10.1371/journal.pone.0021307.
33. Melchers WJ, Hoenderop JG, Bruins SH, Pleij CW, Pilipenko EV, Agol VI, Galama JM. 1997. Kissing of the two predominant hairpin loops in the coxsackie B virus 3' untranslated region is the essential structural feature of the origin of replication required for negative-strand RNA synthesis. J Virol 71:686-696.
34. Kozak M. 1981. Possible role of flanking nucleotides in recognition of the AUG initiator codon by eukaryotic ribosomes. Nucleic Acids Res 9:5233-5252. http://dx.doi.org/10.1093/nar/9.20.5233.
35. Harkins S, Cornell CT, Whitton JL. 2005. Analysis of translational initiation in coxsackievirus B3 suggests an alternative explanation for the high frequency of R+4 in the eukaryotic consensus motif. J Virol 79:987-996. http://dx.doi.org/10.1128/JVI.79.2.987-996.2005.